165 related articles for article (PubMed ID: 37522264)
21. CDK redundancy guarantees cell cycle progression in Rb-negative tumor cells independently of their p16 status.
Santamariña M; Hernández G; Zalvide J
Cell Cycle; 2008 Jul; 7(13):1962-72. PubMed ID: 18604173
[TBL] [Abstract][Full Text] [Related]
22. Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts.
Stein GH; Drullinger LF; Soulard A; Dulić V
Mol Cell Biol; 1999 Mar; 19(3):2109-17. PubMed ID: 10022898
[TBL] [Abstract][Full Text] [Related]
23. Dual inactivation of RB and p53 pathways in RAS-induced melanomas.
Bardeesy N; Bastian BC; Hezel A; Pinkel D; DePinho RA; Chin L
Mol Cell Biol; 2001 Mar; 21(6):2144-53. PubMed ID: 11238948
[TBL] [Abstract][Full Text] [Related]
24. The expression of p16(INK4a), the product of a tumor suppressor gene for melanoma, is upregulated in human melanocytes by UVB irradiation.
Piepkorn M
J Am Acad Dermatol; 2000 May; 42(5 Pt 1):741-5. PubMed ID: 10775848
[TBL] [Abstract][Full Text] [Related]
25. Reactive oxygen species promotes cellular senescence in normal human epidermal keratinocytes through epigenetic regulation of p16(INK4a.).
Sasaki M; Kajiya H; Ozeki S; Okabe K; Ikebe T
Biochem Biophys Res Commun; 2014 Sep; 452(3):622-8. PubMed ID: 25181340
[TBL] [Abstract][Full Text] [Related]
26. Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.
Konecny GE; Winterhoff B; Kolarova T; Qi J; Manivong K; Dering J; Yang G; Chalukya M; Wang HJ; Anderson L; Kalli KR; Finn RS; Ginther C; Jones S; Velculescu VE; Riehle D; Cliby WA; Randolph S; Koehler M; Hartmann LC; Slamon DJ
Clin Cancer Res; 2011 Mar; 17(6):1591-602. PubMed ID: 21278246
[TBL] [Abstract][Full Text] [Related]
27. Activation of the retinoblastoma tumor suppressor mediates cell cycle inhibition and cell death in specific cervical cancer cell lines.
Bourgo RJ; Braden WA; Wells SI; Knudsen ES
Mol Carcinog; 2009 Jan; 48(1):45-55. PubMed ID: 18506774
[TBL] [Abstract][Full Text] [Related]
28. C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells.
Zhuang D; Mannava S; Grachtchouk V; Tang WH; Patil S; Wawrzyniak JA; Berman AE; Giordano TJ; Prochownik EV; Soengas MS; Nikiforov MA
Oncogene; 2008 Nov; 27(52):6623-34. PubMed ID: 18679422
[TBL] [Abstract][Full Text] [Related]
29. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts.
Alcorta DA; Xiong Y; Phelps D; Hannon G; Beach D; Barrett JC
Proc Natl Acad Sci U S A; 1996 Nov; 93(24):13742-7. PubMed ID: 8943005
[TBL] [Abstract][Full Text] [Related]
30. Functional analysis of wild-type and malignant glioma derived CDKN2Abeta alleles: evidence for an RB-independent growth suppressive pathway.
Arap W; Knudsen E; Sewell DA; Sidransky D; Wang JY; Huang HJ; Cavenee WK
Oncogene; 1997 Oct; 15(17):2013-20. PubMed ID: 9366518
[TBL] [Abstract][Full Text] [Related]
31. p16(INK) (4a) deficiency promotes DNA hyper-replication and genetic instability in melanocytes.
Fung C; Pupo GM; Scolyer RA; Kefford RF; Rizos H
Pigment Cell Melanoma Res; 2013 Mar; 26(2):236-46. PubMed ID: 23279822
[TBL] [Abstract][Full Text] [Related]
32. Recurrent patterns of dual RB and p53 pathway inactivation in melanoma.
Yang G; Rajadurai A; Tsao H
J Invest Dermatol; 2005 Dec; 125(6):1242-51. PubMed ID: 16354195
[TBL] [Abstract][Full Text] [Related]
33. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.
Bartkova J; Lukas J; Guldberg P; Alsner J; Kirkin AF; Zeuthen J; Bartek J
Cancer Res; 1996 Dec; 56(23):5475-83. PubMed ID: 8968104
[TBL] [Abstract][Full Text] [Related]
34. Evidence for a CDK4-dependent checkpoint in a conditional model of cellular senescence.
Brookes S; Gagrica S; Sanij E; Rowe J; Gregory FJ; Hara E; Peters G
Cell Cycle; 2015; 14(8):1164-73. PubMed ID: 25695870
[TBL] [Abstract][Full Text] [Related]
35. Oncogene-induced senescence does not require the p16(INK4a) or p14ARF melanoma tumor suppressors.
Haferkamp S; Scurr LL; Becker TM; Frausto M; Kefford RF; Rizos H
J Invest Dermatol; 2009 Aug; 129(8):1983-91. PubMed ID: 19212341
[TBL] [Abstract][Full Text] [Related]
36. Differential expression of the cyclin-dependent kinase inhibitors p16 and p21 in the human melanocytic system.
Wang Y; Becker D
Oncogene; 1996 Mar; 12(5):1069-75. PubMed ID: 8649798
[TBL] [Abstract][Full Text] [Related]
37. Control of the replicative life span of human fibroblasts by p16 and the polycomb protein Bmi-1.
Itahana K; Zou Y; Itahana Y; Martinez JL; Beausejour C; Jacobs JJ; Van Lohuizen M; Band V; Campisi J; Dimri GP
Mol Cell Biol; 2003 Jan; 23(1):389-401. PubMed ID: 12482990
[TBL] [Abstract][Full Text] [Related]
38. Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.
Reiter FP; Denk G; Ziesch A; Ofner A; Wimmer R; Hohenester S; Schiergens TS; Spampatti M; Ye L; Itzel T; Munker S; Teufel A; Gerbes AL; Mayerle J; De Toni EN
Cell Oncol (Dordr); 2019 Oct; 42(5):705-715. PubMed ID: 31250364
[TBL] [Abstract][Full Text] [Related]
39. Sequential extension of proliferative lifespan in human fibroblasts induced by over-expression of CDK4 or 6 and loss of p53 function.
Morris M; Hepburn P; Wynford-Thomas D
Oncogene; 2002 Jun; 21(27):4277-88. PubMed ID: 12082615
[TBL] [Abstract][Full Text] [Related]
40. S-phase lengthening induced by p16(INK4a) overexpression in malignant cells with wild-type pRb and p53.
Chien WW; Domenech C; Catallo R; Salles G; Ffrench M
Cell Cycle; 2010 Aug; 9(16):3286-96. PubMed ID: 20703084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
